SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 23, 2004
IntraBiotics Pharmaceuticals, Inc.
| Delaware |
0-29993 |
94-3200380 |
||
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
2483 East Bayshore Road, Suite 100
Palo Alto, California 94303
(Address of principal executive offices and zip code)
Registrant’s telephone number, including area code: (650) 526-6800
Not Applicable
| Item 5. Other Events. | ||||||||
| Item 7. Financial Statements and Exhibits. | ||||||||
| SIGNATURE | ||||||||
| INDEX TO EXHIBITS | ||||||||
| EXHIBIT 99.1 | ||||||||
Item 5. Other Events.
On June 23, 2004, IntraBiotics Pharmaceuticals, Inc. announced that it had stopped its iseganan trial in ventilator-associated pneumonia for safety reasons. A copy of the related press release is being filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference in its entirety.
Item 7. Financial Statements and Exhibits.
| (c) | Exhibits. The following documents are filed as exhibits to this report: |
| 99.1 | Press Release, dated June 23, 2004, entitled “IntraBiotics Stopped Iseganan Trial in Ventilator-Associated Pneumonia for Safety Reasons.” |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| INTRABIOTICS PHARMACEUTICALS, INC. |
||||
| Date: June 24, 2004 | /s/ David Tucker | |||
| David Tucker | ||||
| Principal Financial Officer | ||||